Prophylactic Pancreatic Stent Placement for Endoscopic Duodenal Ampullectomy: A Single-Center Retrospective Study.
- Author:
Woo Ik CHANG
1
;
Yang Won MIN
;
Hwan Sic YUN
;
Kwang Hyuck LEE
;
Jong Kyun LEE
;
Kyu Taek LEE
;
Poong Lyul RHEE
Author Information
1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. lkhyuck@gmail.com
- Publication Type:Original Article
- Keywords:
Endoscopic papillectomy;
Pancreatic stent;
Postprocedure pancreatitis
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Ampulla of Vater/surgery;
Cholangiopancreatography, Endoscopic Retrograde;
Common Bile Duct Neoplasms/*surgery;
Endoscopy/methods;
Female;
Humans;
Male;
Middle Aged;
Pancreatic Ducts/surgery;
Pancreatitis/*prevention & control;
Postoperative Complications/*prevention & control;
Retrospective Studies;
Sphincterotomy, Endoscopic/methods;
*Stents
- From:Gut and Liver
2014;8(3):306-312
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: We investigated the efficacy of prophylactic pancreatic stent placement for preventing postprocedure pancreatitis in patients undergoing endoscopic papillectomy. METHODS: This retrospective study included 82 consecutive patients who underwent endoscopic papillectomy for benign ampullary neoplasm at Samsung Medical Center between August 2002 and June 2011. The patients were subdivided into two groups, namely, those who received prophylactic pancreatic stent placement and those who did not. Patient demographics, baseline blood test, tumor characteristics, and endoscopic treatment data were collected. The primary endpoint was postprocedure pancreatitis. RESULTS: There was no difference in the development of postprocedure pancreatitis between the stent group and the no stent group (6/54, 10.5% and 2/28, 7.14%, respectively; p=1.00). At baseline, there were no significant differences between the two groups in terms of their risk factors for pancreatitis except pancreatic duct dye injection. The stent group was more likely to have dye injection than the nonstent group (100% vs 42.8%, p<0.001). However, in a logistic regression analysis, no significant difference was observed in the risk factors for pancreatitis including dye injection. CONCLUSIONS: Our data suggest that routine prophylactic pancreatic duct stent placement in all patients undergoing endoscopic papillectomy may not be necessary and that large-scale prospective studies are required to identify the subgroup of patients who would benefit.
